Financials in USD. Standardized financial statements.
A compact view of how Beta Bionics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue? | $100.25M | $65.12M | $11.99M | $179,000 |
| Revenue Growth? | +53.9% | +442.9% | +6601.1% | 0.0% |
| Cost of Revenue? | $44.71M | $29.24M | $5.69M | $0 |
| Gross Profit? | $55.54M | $35.89M | $6.31M | $179,000 |
| Gross Margin? | +55.4% | +55.1% | +52.6% | +100.0% |
| Operating Expenses? | $127.22M | $81.14M | $42.16M | $66.02M |
| Operating Income? | -$71.68M | -$45.25M | -$35.85M | -$65.84M |
| EBITDA? | -$73.20M | -$44.10M | -$34.62M | -$63.40M |
| Income Before Tax | -$73.20M | -$54.76M | -$44.10M | -$64.75M |
| Income Tax Expense | $1,000 | $0 | $0 | $0 |
| Net Income? | -$73.20M | -$54.76M | -$44.10M | -$64.75M |
| EPS? | $-1.81 | $-8.60 | $-8.31 | $-12.96 |
| Diluted EPS? | $-1.81 | $-8.60 | $-8.31 | $-12.96 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality